Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 12/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91333 | 0.88 | RIOK2 (0.57) | NR3C2L3MBTL1PIK3C3 | |
| SCHEMBL6951830 | 0.86 | NR3C2 (0.54) | NR3C2L3MBTL1MAPK14 | |
| SCHEMBL29507273 | 0.85 | L3MBTL1 (0.52) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL7671508 | 0.85 | L3MBTL1 (0.52) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL501285 | 0.85 | L3MBTL1 (0.52) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL30893838 | 0.83 | L3MBTL1 (0.50) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL21847287 | 0.83 | L3MBTL1 (0.50) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL2642713 | 0.83 | L3MBTL1 (0.50) | NR3C2L3MBTL1MAPK14PIK3C3 | |
| SCHEMBL4309482 | 0.83 | L3MBTL1 (0.50) | NR3C2L3MBTL1PIK3C3 | |
| SCHEMBL2642714 | 0.83 | LOXL2 (0.58) | NR3C2L3MBTL1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | NR3C2 2424/4885L3MBTL1 3978/4885MAPK14 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.